• 543 Citations
  • 10 h-Index
19992023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

The laboratory of Dr. Daniel Morgan focuses on understanding the mechanisms responsible for the different roles of cannabinoid signaling in human health and disease. One of the lab's main areas of interest is to better understand the mechanisms responsible for tolerance to cannabinoids such as delta-9-tetrahydrocannabinol (∆9-THC) in pathological models of pain including agonist-specific differences in the mechanisms responsible for cannabinoid tolerance. Previous studies have shown that receptor desensitization is involved in the development of tolerance for GPCR-directed agonists in vivo. The laboratory’s work utilizes a novel “knock-in” mouse line that expresses a desensitization-resistant form of the cannabinoid receptor 1 (CB1) to investigate tolerance for ∆9-THC and two synthetic cannabinoid agonists, WIN 55,212-2 and CP55,950. Results from the lab show that tolerance to WIN 55,212-2 is mediated exclusively through this classical mechanism of desensitization, whereas tolerance to ∆9-THC is only partially attenuated when this mechanism is disrupted. Interestingly, data strongly suggests that tolerance to ∆9-THC, but not the other two synthetic agonists, is partially mediated through a c-Jun N-terminal kinase (JNK) signaling pathway. The laboratory is currently engaged in work to better understand the molecular mechanisms responsible for this novel form of JNK-mediated ∆9-THC tolerance. The laboratory is also engaged in a second major project to understand the role of CB1 internalization and trafficking in cannabinoid tolerance and dependence. This project involves using a second “knock-in” mouse that expresses an internalization-deficient form of CB1 to study tolerance and physical dependence for ∆9-THC, WIN 55,212-2 and CP55,950.

Education/Academic qualification

Postdoctoral Training, Indiana Unviersity

20072010

Senior Fellow, University of Washington School of Medicine

20042007

PhD, Rutgers University

19972004

BA, Grinnell College

19931997

External positions

Session Chair and Program Committee, International Cannabinoid Research Society

Jan 1 2018

Session Chair and Program Committee, International Cannabinoid Research Society

2018

Program Committee, Winter Conference on Brain Research

Jan 1 2017Jan 1 2019

Program Committee, Winter Conference on Brain Research

20172019

Neuropharmacology Executive Committee, American Society for Pharmacology and Experimental Therapeutics

Jan 1 2016Jan 1 2019

Neuropharmacology Executive Committee, American Society for Pharmacology and Experimental Therapeutics

20162019

Fingerprint Dive into the research topics where Daniel Morgan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Cannabinoid Receptors Medicine & Life Sciences
Cannabinoids Medicine & Life Sciences
Dronabinol Medicine & Life Sciences
Morphine Medicine & Life Sciences
Endocannabinoids Medicine & Life Sciences
mu Opioid Receptor Medicine & Life Sciences
Proprotein Convertase 1 Medicine & Life Sciences
JNK Mitogen-Activated Protein Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2023

Mechanisms of cannabinoid tolerance

Morgan, D. & Guindon, J.

National Institutes of Health

9/1/187/31/23

Project: Research project

Dronabinol
Cannabinoids
JNK Mitogen-Activated Protein Kinases
Neuralgia
Cannabinoid Receptor Agonists
Cannabinoid Receptors
Dronabinol
Cannabinoids
rimonabant
Down-Regulation
Dronabinol
Cannabinoids
Phosphotransferases
Analgesics
Microarray Analysis

Research Output 1999 2019

  • 543 Citations
  • 10 h-Index
  • 23 Article
  • 1 Editorial
  • 1 Short survey
  • 1 Review article

Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain

Blanton, H. L., Brelsfoard, J., DeTurk, N., Pruitt, K., Narasimhan, M., Morgan, D. & Guindon, J., Jun 1 2019, In : Drugs. 79, 9, p. 969-995 27 p.

Research output: Contribution to journalReview article

Cannabinoids
Neuralgia
Peripheral Nervous System Diseases
Drug Therapy
Neoplasms
1 Citation (Scopus)

Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice

Nealon, C. M., Henderson-Redmond, A. N., Hale, D. E. & Morgan, D., Apr 1 2019, In : Neuropharmacology. 148, p. 151-159 9 p.

Research output: Contribution to journalArticle

Cannabinoid Receptors
Cannabinoid Receptor Agonists
G-Protein-Coupled Receptor Kinase 1
Phosphorylation
Arrestin
4 Citations (Scopus)

Alterations in nociception and morphine antinociception in mice fed a high-fat diet

Nealon, C. M., Patel, C., Worley, B. L., Henderson-Redmond, A. N., Morgan, D. & Czyzyk, T. A., Apr 1 2018, In : Brain Research Bulletin. 138, p. 64-72 9 p.

Research output: Contribution to journalArticle

Nociception
High Fat Diet
Morphine
Tail
Induced Hypothermia
1 Citation (Scopus)

Increased ethanol drinking in “humanized” mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms

Henderson-Redmond, A. N., Lowe, T. E., Tian, X. B. & Morgan, D., Apr 1 2018, In : Brain Research Bulletin. 138, p. 12-19 8 p.

Research output: Contribution to journalArticle

mu Opioid Receptor
Drinking
Ethanol
Hypnotics and Sedatives
Righting Reflex
2 Citations (Scopus)

Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test

Lafleur, R. A., Wilson, R., Morgan, D. & Henderson-Redmond, A. N., Jan 1 2018, In : NeuroReport. 29, 6, p. 447-452 6 p.

Research output: Contribution to journalArticle

Dronabinol
Pain Measurement
Sex Characteristics
Cannabinoids
Cannabinoid Receptors